Artemis Institute for Clinical Research | San Diego, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term.
Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia.
Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team.
The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Further exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
1,401 participants in 1 patient group
Loading...
Central trial contact
Boehringer Ingelheim
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal